RVTY - Revvity, Inc. News

Barclays Maintains Equal-Weight on Revvity, Raises Price Target to $160

Barclays analyst Luke Sergott maintains Revvity (NYSE:RVTY) with a Equal-Weight and raises the pr

Revvity Nears 52-Week High, but This Analyst Thinks Stock Can Climb Another 20%

William Blair initiates Revvity (RVTY) at Outperform, citing AI tailwinds, life sciences recovery, a

Revvity to Host Investor Day

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will host its 2026 I

Revvity (RVTY) Upgraded to Buy: What Does It Mean for the Stock?

Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflecte

Revvity to Hold Earnings Call on November 3, 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release it

Revvity (NYSE:RVTY) Hits New 12-Month High – Here’s Why

Revvity Inc. (NYSE: RVTY - Get Free Report) shares reached a new 52-week high on Thursday. The stock

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

RVTY's diagnostics growth, AI-driven demand and life sciences expansion support its outlook, though

RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection

Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP pla

Full Transcript: Revvity Q2 2026 Earnings Call

Revvity (NYSE:RVTY) reported second-quarter financial results on Tuesday. The transcript from the co

Here’s How Much You Would Have Made Owning Revvity Stock In The Last 15 Years

Revvity (NYSE:RVTY) has outperformed the market over the past 15 years by 1.11% on an annualized bas

Revvity Rolls Out GSP T1D 3plex Kit

Revvity, Inc. (NYSE: RVTY) today announced the launch of the GSP® T1D 3plex kit, a fully automated,

Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced the launch of the GSP® T

Reviewing Codexis (NASDAQ:CDXS) & Revvity (NYSE:RVTY)

Revvity (NYSE: RVTY - Get Free Report) and Codexis (NASDAQ: CDXS - Get Free Report) are both healthc

Revvity Inc. $RVTY Shares Acquired by State Street Corp

State Street Corp boosted its stake in Revvity Inc. (NYSE: RVTY) by 0.8% during the undefined quarte

Fed Raises Rates, Yields Hit 2007 Highs as Fuel Costs Set Records: This Week On Wall Street

The Fed hiked for the first time since 2023; the 10-year yield touched 5.04%, and record diesel pric

Critical Survey: Revvity (NYSE:RVTY) vs. Cytek Biosciences (NASDAQ:CTKB)

Revvity (NYSE: RVTY - Get Free Report) and Cytek Biosciences (NASDAQ: CTKB - Get Free Report) are bo

Here’s How Much You Would Have Made Owning Revvity Stock In The Last 15 Years

Revvity (NYSE:RVTY) has outperformed the market over the past 15 years by 1.11% on an annualized bas

Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?

Revvity (RVTY) was a big mover last session on higher-than-average trading volume. The latest trend

10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today

The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi p

seekingalpha.com

Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript

seekingalpha.com

Revvity, Inc. (RVTY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Revvity Inc. $RVTY Shares Acquired by California State Teachers Retirement System

California State Teachers Retirement System increased its holdings in Revvity Inc. (NYSE: RVTY) by 1

Amundi Trims Holdings in Revvity Inc. $RVTY

Amundi lowered its position in Revvity Inc. (NYSE: RVTY) by 7.2% in the second quarter, according to

Revvity to Acquire Human Cell Design to Boost Metabolic Discovery

RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and p

Why Revvity (RVTY) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t

seekingalpha.com

Revvity, Inc. (RVTY) Presents at Wells Fargo 21st Annual Healthcare Conference Prepared Remarks Tran

Revvity Bets on GLP-1 Boom With Human Cell Design Acquisition

Revvity buys Human Cell Design to expand diabetes and GLP-1 drug discovery tech. Acquisition expecte

Revvity To Acquire French Biotech Firm Human Cell Design To Gain Exposure To Human Cell Models And P

The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Scienc

Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Dru

WALTHAM, Mass.--(BUSINESS WIRE)-- #AI--Revvity, Inc. (NYSE: RVTY) today announced it has entered int

Keybanc Maintains Overweight on Revvity, Raises Price Target to $165

Keybanc analyst Paul Knight maintains Revvity (NYSE:RVTY) with a Overweight and raises the price

Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?

Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but pre

RBC Capital Initiates Coverage On Revvity with Sector Perform Rating, Announces Price Target of $135

RBC Capital analyst Dan Leonard initiates coverage on Revvity (NYSE:RVTY) with a Sector Perform r

Evercore ISI Group Maintains Outperform on Revvity, Raises Price Target to $126

Evercore ISI Group analyst Vijay Kumar maintains Revvity (NYSE:RVTY) with a Outperform and raises

Transcript: Revvity Q2 2026 Earnings Conference Call

Revvity (NYSE:RVTY) held its second-quarter earnings conference call on Tuesday. Below is the comple

Revvity Raises FY2026 Adj EPS Guidance from $5.20-$5.30 to $5.30-$5.40 vs $5.27 Est; Raises FY2026 S

Revvity (NYSE:RVTY) raises FY2026 Adj EPS guidance from $5.20-$5.30 to $5.30-$5.40 vs $5.27 analyst

Revvity Q2 Adj. EPS $1.41 Beats $1.22 Estimate, Sales $729.688M Beat $709.035M Estimate

Revvity (NYSE:RVTY) reported quarterly earnings of $1.41 per share which beat the analyst consensus

Evercore ISI Group Maintains Outperform on Revvity, Raises Price Target to $125

Evercore ISI Group analyst Vijay Kumar maintains Revvity (NYSE:RVTY) with a Outperform and raises

Bernstein Reinstates Market Perform on Revvity, Announces $115 Price Target

Bernstein analyst Eve Burstein reinstates Revvity (NYSE:RVTY) with a Market Perform and announces

Revvity Launches Signals AI

Scientists can now search, understand and act on complex R&D data in natural language by leverag

Barclays Maintains Equal-Weight on Revvity, Raises Price Target to $105

Barclays analyst Luke Sergott maintains Revvity (NYSE:RVTY) with a Equal-Weight and raises the pr

JP Morgan Maintains Neutral on Revvity, Lowers Price Target to $90

JP Morgan analyst Casey Woodring maintains Revvity (NYSE:RVTY) with a Neutral and lowers the pric

TD Cowen Maintains Buy on Revvity, Raises Price Target to $120

TD Cowen analyst Dan Brennan maintains Revvity (NYSE:RVTY) with a Buy and raises the price target

Stifel Maintains Hold on Revvity, Lowers Price Target to $100

Stifel analyst Daniel Arias maintains Revvity (NYSE:RVTY) with a Hold and lowers the price target

Earnings Scheduled For May 5, 2026

Revvity Lowers FY2026 Adj EPS Guidance from $5.35-$5.45 to $5.20-$5.30 vs $5.39 Est; Lowers FY2026 S

Revvity (NYSE:RVTY) lowers FY2026 Adj EPS guidance from $5.35-$5.45 to $5.20-$5.30 vs $5.39 analyst

Revvity Q1 Adj. EPS $1.06 Beats $1.02 Estimate, Sales $711.118M Beat $705.134M Estimate.

Revvity (NYSE:RVTY) reported quarterly earnings of $1.06 per share which beat the analyst consensus

Packaging Corp Of America To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday

Needham analyst Rick Patel maintained a Buy rating. Steven Madden shares closed at $47.27 on Friday.

Baird Maintains Outperform on Revvity, Lowers Price Target to $125

Baird analyst Catherine Ramsey maintains Revvity (NYSE:RVTY) with a Outperform and lowers the pri

9 Health Care Stocks With Whale Alerts In Today's Session